News

Florida-based neurologist Donal Negroski, MD, presents data from an aging MS patient population looking for treatment options under Medicare.

Fred Lublin, MD, the CMSC Presidential Lecture speaker, offers updated views on how to define MS clinical progression.

In comparison with adults on ocrelizumab, pediatric patients experienced no clinical relapses and a safety profile that was similar to what was previously observed.

A recent survey reported a high prevalence of burnout among physicians treating patients with multiple sclerosis, highlighting long work hours as one of the key factors.

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Katherine Peters, PhD. [LISTEN TIME: 13 minutes]

Host Jeffrey Wilken, PhD, chats with Fred Lublin, MD; Brian Hutchinson, PT, MSCS; and Robert Motl, PhD, about the second day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

Crystal, a patient living with chronic inflammatory demyelinating polyneuropathy and one of the faces of the Shining Through CIDP awareness campaign, discussed the diagnostic challenges associated with the rare disease.

Within a subgroup of those older than 50 years, most patients who switched to cladribine were relapse free at follow-up, with no new safety signals observed.

The clinical research director of the UCSF Multiple Sclerosis Center talked about results from clinical trials assessing BTK inhibitors in relapsing multiple sclerosis and the ongoing research to explore more effective treatments. [WATCH TIME: 5 minutes]

MS does not carry an increased risk of high-risk pregnancy, but many clinicians are unclear about best practices for managing these patients.

CMSC Kurtzke Lecturer Darin Okuda, MD, demonstrates innovative ways to rethink MRI use in MS.

In a new analysis of the CHIMES trial, ocrelizumab displayed a trend toward improved work productivity among minority patients with relapsing multiple sclerosis.

Mike Hooven, chairman and CEO of Enable Injections, and Randall Moreadith, MD, PhD, chief development officer of Serina Therapeutics, provided insight on the development plans of SER-252, an investigational apomorphine therapy for advanced Parkinson disease.

The newly added tablet strengths allow for greater flexibility when selecting or adjusting dosing for deutetrabenazine.

Host Jeffrey Wilken, PhD, chats with Robert Naismith, MD; Jiwon Oh, MD, PhD; and Anthony Traboulsee, MD, about the first day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

Over a 24-month treatment period, patients on cladribine demonstrated no axonal loss evident on OCT, with reductions in cerebrospinal fluid neurofilament light and impacts on oligoclonal bands.

The clinical research director of the UCSF Multiple Sclerosis Center discussed the early-onset progression in multiple sclerosis and emphasized the need for targeted therapies in this patient population. [WATCH TIME: 6 minutes]

Nearly half of patients on diphenhydramine, dexamethasone, and famotidine experienced moderate to severe decreased alertness vs only 12.9% of those on cetirizine, dexamethasone, and famotidine.

Over a 5-year treatment period, patients on ofatumumab, regardless of race or ethnicity, demonstrated significant reductions in neurofilament light and achieved consistent rates of NEDA-3.

Howard Rosen, chief executive officer of the American Headache Society, provided commentary on the upcoming annual meeting and the unique types of educational sessions clinicians can look forward to.

Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.

The associate professor of neurology at Harvard Medical School talked about results from a recent study that evaluated the efficacy of inebilizumab versus rituximab in treating NMOSD.

Following the mixed results, NS Pharma is working with the FDA to determine how to proceed with viltolarsen.

Scott Newsome, DO, director of the Stiff Person Syndrome Center and professor of neurology at Johns Hopkins Medicine, provided clarity on the 1-year data of the OCARINA II study assessing subcutaneous ocrelizumab.

The FDA granted fast track designation to TPN-101, an investigational therapy for progressive supranuclear palsy, based on promising phase 2a study results.

The director of research in the Jane and John Justin Neurosciences Center at Cook Children's Health Care System talked about ongoing research on biomarkers to enhance treatment and improve cognitive outcomes. [WATCH TIME: 6 minutes]

As part of our monthly clinician spotlight, NeurologyLive® highlighted neuromuscular disorder expert Merit Cudkowicz, MD, MSc, chair of neurology at Massachusetts General Hospital.

Overall, a significantly greater amount of patients on Andexanet had hematoma volume expansion of 35% or less; however, these patients had greater risk of thrombolytic events and lower modified Rankin scale scores at 30 days.

Here's some of what is coming soon to NeurologyLive® this week.

The 38th CMSC Annual Meeting is set to be held May 29-June 1, 2024, in Nashville, Tennessee. The International Journal of MS Care has published the abstracts.